海外の治験の状況「1」での検索結果
10032件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- First-line Chemotherapy for Recurrent Cervical Cancer
- Recurrent Cervical Carcinoma;Persistent Advanced Cervical Carcinoma;Chemotherapy;Vascular Endothelial Growth Factor 2 Inhibitor;Apatinib;Targeted Therapy
- China
- 2019-12-04
Recruiting
- Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen
- Advanced Biliary Tract Tumors
- China
- 2019-12-06
Not recruiting
- Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
- Locally Advanced or Metastatic NSCLC
- China
- 2019-12-19
Not recruiting
- Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
- Advanced Biliary Tract Cancer
- China
- 2019-12-22
Not Recruiting
- Programmed cell death 1 (pd-1) inhibitors combined with different doses hypofractionated radiotherapy for recurrent and metastatic head and neck squamous cell carcinoma: a randomized controlled clinical study
- recurrent and metastatic head and neck squamous cell carcinoma
- China
- 2019-12-28
Recruiting
- Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
- Non-Small-Cell Lung
- Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Jordan, Korea, Republic of, Lebanon, Netherlands, Poland, Russian Federation, Singapore, Spain, Taiwan, United States
- 2018-07-25
Recruiting
- The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- Immune Thrombocytopenia
- China
- 2019-12-30
Not Recruiting
- A Phase III Trial for Mefatinib (MET-306) Versus Gefitinib in the Treatment of 1st Line EGFR Mutation of Patients with Advanced Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- China
- 2020-01-02
Not Recruiting
- A phase Ib study for efficacy and safety of Mefatinib (MET-306) for the treatment of 1st Line EGFR Mutation in Patients with advanced non-small cell lung cancer
- Advanced Non-Small Cell Lung Cancer
- China
- 2020-01-12
Not Recruiting
- A phase II trial for Mefatinib (MET-306) 60mg or 80mg in the treatment of 1st Line EGFR Mutation in Patients with advanced non-small cell lung cancer
- Advanced Non-Small Cell Lung Cancer
- China
- 2020-01-12
Not recruiting
- Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
- Colorectal Cancer
- China
- 2020-01-13
Not Recruiting
- Efficacy and safety of nab-paclitaxel combined with apatinib in the second-line treatment of advanced gastric cancer
- Gastric Cancer
- China
- 2020-01-11
Not Recruiting
- Comparing the the level of a growth promoting factor(TGF beta 1) in the gum fluid of bone defects treated using a membrane derived from animal tissues and a membrane derived from human fetal sac
- Certain infectious and parasitic diseases
- India
- 2020-01-30
Recruiting
- A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer
- China
- 2020-01-23
Not recruiting
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
- Non-Small Cell Lung Cancer
- Korea, Republic of
- 2020-01-14
Authorised
- Study to evaluate 2 types of treatment as first line treatment (masitinib + gemcitabine or placebo + gemcitabine ) and 2 types of treatment as second line treatment (masitinib + FOLFIRI 3 or placebo + FOLFIRI 3) in the treatment of patients with with non resectable locally advanced or metastatic pancreatic cancer.
- Non resectable locally advanced or metastatic pancreatic cancer MedDRA version: 18.0 Level: PT Classification code 10033610 Term: Pancreatic carcinoma metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Germany, Greece, Hong Kong, Hungary, India, Italy, Korea, Republic of, Malaysia, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Tunisia, Ukraine, United Kingdom, United States
- 2014-01-09
Not recruiting
- Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
- Hodgkin Disease;Lymphoma, Large-Cell, Anaplastic
- China
- 2016-10-18
- LUX-LUNG 8: A RANDOMIZED, OPEN-LABEL PHASE III TRIAL OF AFATINIB VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG AS SECOND-LINE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- Argentina, Austria, Canada, Chile, China, Denmark, France, Germany, Greece, Hungary, India, Ireland, Italy, Korea North, Mexico, Netherlands, Portugal, Singapore, Spain, Taiwan, Turkey, United Kindgdom, United States
- 2012-05-24
Not Recruiting
- A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
- Hepatocellular Carcinoma;C22.0 - Malignant neoplasm: Liver cell carcinoma
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Philippines, Portugal, Romania, Spain, Sweden, Switzerland, Taiwan, Province of China, Thailand, United States
- 2012-05-09
Recruiting
- LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy
- Carcinoma, Non-Small-Cell Lung;C34 - Malignant neoplasm of bronchus and lung
- Argentina, Austria, Canada, Chile, China, Denmark, France, Germany, Greece, Hungary, India, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Singapore, Spain, Taiwan, Province of China, Turkey, United Kingdom, United States
- 2012-05-02